Abstract: The invention generally relates to the fields of drug delivery and cell capture. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for drug delivery vehicles and/or cell capture.

Abstract: A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.

Abstract: A hydrogel material composition includes: (1) an alginate (or other cross-linking polymer) material; (2) an optional ?-hydroxy carboxylate material; and (3) an iron cation material. The hydrogel material composition with or without the ?-hydroxy-carboxylate material may be used in a photolithographic imaging application or a photorelease application within the context of a photoirradiation induced reduction/oxidation reaction of an iron (III) cation material to form an iron (II) cation material.

Abstract: Composite biomaterials are described, which can be implanted in the human body in various branches of surgery or on the skin in dermocosmetic surgery, which can be formed as membranes or felts and which have properties of rate of absorption in the body and of hydrophilicity that can be modulated.

Abstract: Described herein are compositions useful for protecting the skin from the sun. The compositions comprise cosmetic ingredients such as zinc oxide, titanium dioxide, butyloctyl salicylate, and a dermatologically acceptable vehicle. The compositions may further comprise additional ingredients such as cyclopentasiloxane, neopentyl glycol diheptanoate, butylene glycol, caprylyl methicone, PEG-9 polydimethylsiloxyethyl dimethicone, glycerin, polyglyceryl-6 polyricinoleate, lauric acid, aluminum hydroxide, potassium sorbate, and citric acid.

Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.

Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.

Abstract: The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents.

Abstract: The invention relates to microcapsules having a particle size distribution that has at least two maxima, wherein the main maximum of the particle size lies in the range of 5 to 100 ?m and wherein the volume assumed by the microcapsules that have a particle size less than ¼ of the particle size of the main maximum is greater than approximately 20% of the total volume of the microcapsules.

Abstract: A solid oral pharmaceutical composition in the form of at least one tablet, the tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent, the composition allowing continuous release in vivo over a period from after a quarter of an hour and up to twelve hours after taking a single dose, for use thereof as a medicament, in particular in the treatment and/or prevention of urinary lithiasis and related diseases, occurring at a physiological pH and/or during urinary acidosis and/or during hypobicarbonataemia and/or during hypocitraturia and/or during hypercalciuria and/or during hyperoxaluria.

Abstract: The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

Abstract: A method of treating or preventing neurological injury in a subject who has suffered a stroke is described. The method includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject. Methods for prophylaxis against neurological injury from stroke, and methods for treating or preventing cardiovascular disease by administration of a therapeutically effective amount of cerium oxide nanoparticles are also described.

Abstract: A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); a physiologically acceptable polymer (B) obtainable by polymerization of a monomer composition comprising an ethylenically unsaturated monomer bearing an anionic functional group, in protonated form or a physiologically acceptable salt thereof; a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the polymer (B) and the polyalkylene oxide (C).

Abstract: The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same.

Abstract: Disclosed are nanotopography-based methods and devices for interacting with a component of epithelial tissue and increasing the permeability of the tissue. Devices include structures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be beneficially utilized for delivery of an agent to a cell or tissue. Devices may be utilized to directly or indirectly alter cell behavior through the interaction of a fabricated nanotopography with the components of epithelial tissue.

Abstract: The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices.

Abstract: The compositions and methods of this invention relate to a rinse-off skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 1000 ?m, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 ?m; at least one cleansing agent selected from the group consisting of a saponified fat and a surfactant; and a cosmetically acceptable carrier.

Abstract: The compositions and methods of this invention relate to a rinse-off skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 1000 ?m, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 ?m; at least one cleansing agent selected from the group consisting of a saponified fat and a surfactant; and a cosmetically acceptable carrier.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

Abstract: A method for producing powders for inhalation includes a first mixing step of stirring a first active ingredient and a carrier in the presence of a milling medium, and mixing the first active ingredient and the carrier while crumbling the agglomerates of the first active ingredient to obtain a mixture of the carrier and the first active ingredient; and a second mixing step of adding fine powders to the mixture obtained in the first mixing step, and stirring and mixing the mixture and the fine powders in the presence of a milling medium.